Treatment Options, Clinical Pathways, and Collaborative Care: A Multiple Myeloma Update for Managed Care and Specialty Pharmacy Primer

Release date: March 10, 2017
Expiration date: September 30, 2018
Estimated Time to Complete Activity: 1.0 hour
Compatible with all modern browsers and mobile devices

REVIEW BOARD FACULTY



	Jeffrey Dunn, PharmD, MBA Senior Vice President Chief Clinical Officer VRx/MagellanRx Click here for biography

	Carol Ann Huff, MD Associate Professor of Oncology and Medicine Director, Multiple Myeloma Program Medical Director, Department of Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Click here for biography

	Edmund Pezalla, MD, MPH CEO Enlightenment Bioconsulting Click here for biography

TARGET AUDIENCE

Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for multiple myeloma patients including: physicians, pharmacists, registered nurses, and case managers

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants should be able to demonstrate improved ability to:

Evaluate recent clinical data affecting evidence-based treatment guidelines for multiple myeloma (MM)
Demonstrate the value of clinical pathways initiatives as a means of reducing treatment variability and improving clinical and economic outcomes in the management of MM
Implement comprehensive care strategies involving effective communication methods
Integrate innovative oncology pharmacy benefit models with specialty pharmacy management services

ACCREDITATION

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education


	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-18-144-H01-P).

Type of Activity
Application

Continuing Nursing Education

The Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.0 contact hour is provided by the Postgraduate Institute for Medicine.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

*Name of Faculty or Presenter*	*Reported Financial Relationship*
Jeffrey Dunn, PharmD, MBA	No financial interest/relationships relating to the topic of this activity
Carol Ann Huff, MD	Consulting Fees (eg, advisory boards): Glenmark, Karyopharm Contracted Research: Karyopharm, Prothena
Edmund Pezalla, MD, MPH	No financial interest/relationships relating to the topic of this activity

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The Impact Education, LLC planners and managers have nothing to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of March 10, 2017, through September 30, 2018, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Primer

FEE INFORMATION
There is no fee for this educational activity.